Suppr超能文献

听力损失和前庭导水管扩大患者的甲状腺评估。

Evaluation of the thyroid in patients with hearing loss and enlarged vestibular aqueducts.

作者信息

Madeo Anne C, Manichaikul Ani, Reynolds James C, Sarlis Nicholas J, Pryor Shannon P, Shawker Thomas H, Griffith Andrew J

机构信息

Social and Behavioral Research Branch, National Human GenomeResearch Institute, National Institutes of Health, Bethesda, MD 20892-3320, USA.

出版信息

Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):670-6. doi: 10.1001/archoto.2009.66.

Abstract

OBJECTIVE

To evaluate thyroid structure and function in patients with enlargement of the vestibular aqueduct (EVA) and sensorineural hearing loss.

DESIGN

Prospective cohort survey.

SETTING

National Institutes of Health Clinical Center, a federal biomedical research facility.

PATIENTS

The study population comprised 80 individuals, aged 1.5 to 59 years, ascertained on the basis of EVA and sensorineural hearing loss.

MAIN OUTCOME MEASURES

Associations among the number of mutant alleles of SLC26A4; volume and texture of the thyroid; percentage of iodine 123 ((123)I) discharged at 120 minutes after administration of perchlorate in the perchlorate discharge test; and peripheral venous blood levels of thyrotropin, thyroxine, free thyroxine, triiodothyronine, thyroglobulin, antithyroid peroxidase and antithyroglobulin antibodies, and thyroid-binding globulin.

RESULTS

Thyroid volume is primarily genotype dependent in pediatric patients but age dependent in older patients. Individuals with 2 mutant SLC26A4 alleles discharged a significantly (P < or = .001) greater percentage of (123)I compared with those with no mutant alleles or 1 mutant allele. Thyroid function, as measured by serologic testing, is not associated with the number of mutant alleles.

CONCLUSIONS

Ultrasonography with measurement of gland volume is recommended for initial assessment and follow-up surveillance of the thyroid in patients with EVA. Perchlorate discharge testing is recommended for the diagnostic evaluation of patients with EVA along with goiter, nondiagnostic SLC26A4 genotypes (zero or 1 mutant allele), or both.

摘要

目的

评估前庭导水管扩大(EVA)和感音神经性听力损失患者的甲状腺结构和功能。

设计

前瞻性队列研究。

地点

国立卫生研究院临床中心,一家联邦生物医学研究机构。

患者

研究人群包括80名年龄在1.5至59岁之间的个体,基于EVA和感音神经性听力损失确定。

主要观察指标

SLC26A4突变等位基因数量;甲状腺的体积和质地;高氯酸盐释放试验中给予高氯酸盐后120分钟时123碘(123I)的释放百分比;以及促甲状腺激素、甲状腺素、游离甲状腺素、三碘甲状腺原氨酸、甲状腺球蛋白、抗甲状腺过氧化物酶和抗甲状腺球蛋白抗体以及甲状腺结合球蛋白的外周静脉血水平。

结果

甲状腺体积在儿科患者中主要取决于基因型,而在老年患者中取决于年龄。与无突变等位基因或1个突变等位基因的个体相比,具有2个SLC26A4突变等位基因的个体释放的123I百分比显著更高(P≤0.001)。通过血清学检测测量的甲状腺功能与突变等位基因数量无关。

结论

建议对EVA患者进行甲状腺超声检查并测量腺体体积,以进行初始评估和随访监测。对于伴有甲状腺肿、SLC26A4基因型诊断不明确(零个或1个突变等位基因)或两者皆有的EVA患者,建议进行高氯酸盐释放试验以进行诊断评估。

相似文献

9
Hereditary hearing loss with thyroid abnormalities.伴有甲状腺异常的遗传性听力损失
Adv Otorhinolaryngol. 2011;70:43-49. doi: 10.1159/000322469. Epub 2011 Feb 24.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验